Systemic Lupus Erythematosus | Pharmacor | G7 | 2015
Last updated 30 November 2015
Historically, developers of systemic lupus erythematosus (SLE) drugs faced formidable challenges: drug development for a complex, multifaceted, poorly understood disease; regulatory hurdles; a small but heterogeneous population; and a multiplicity of manifestations. Recent positive clinical trial results and the regulatory approval of belimumab (GlaxoSmithKline’s Benlysta)—the first new agent in 50 years—have lowered some development hurdles, and a growing list of emerging agents has ushered in a new era of SLE drug development. We forecast that sales of SLE therapies will increase approximately 2.5-fold during our 2014-2024 forecast period, driven largely by the entry and uptake of premium-priced biologics.
Related Market Assessment Reports
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Multiple Sclerosis – Unmet Need – Unmet Need – Multiple Sclerosis: Nonrelapsing Secondary-Progressive Multiple Sclerosis (US/EU)
No treatments are approved for nonrelapsing secondary-progressive multiple sclerosis (nrSP-MS), an MS disease course in which physical disability accumulates in the absence of superimposed relapses…
Report
Osteoarthritic Pain – Current Treatment – Treatment Algorithms: Claims Data Analysis – Osteoarthritic Pain (US)
Osteoarthritic (OA) pain affects more than 30 million people in the United States, and the aging population and rising obesity rates are expected to drive further increases. Current treatments,…
